Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Meehan

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
The Journal of Pathology|June 20, 2020
SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumorsYibo Xue, Xianbing Zhu, Brian Meehan, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Nature Communications|September 14, 2021
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondriaYibo Xue, Jordan L Morris, Kangning Yang, et al.
Nature Communications|February 6, 2019
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancerYibo Xue, Brian Meehan, Zheng Fu, et al.
Nature Communications|February 6, 2019
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovaryYibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
The Journal of Pathology|June 20, 2020
SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumorsYibo Xue, Xianbing Zhu, Brian Meehan, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Nature Communications|September 14, 2021
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca<sup>2+</sup> flux to mitochondriaYibo Xue, Jordan L Morris, Kangning Yang, et al.
Nature Communications|February 6, 2019
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancerYibo Xue, Brian Meehan, Zheng Fu, et al.
Nature Communications|February 6, 2019
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovaryYibo Xue, Brian Meehan, Elizabeth Macdonald, et al.
Pageof 7